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Lack of mutation in tumour-suppressor gene p53 in gestational
trophoblastic tumours
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Summary The objectives of this study were to better our understanding of the carcinogenesis of gestational
trophoblastic tumours and to investigate the possible presence of mutational alteration of the p53 tumour-
suppressor gene in these tumours. Amplification-based direct DNA sequencing was performed on 14
hydatidiform moles, six invasive moles, eight choriocarcinomas and ten normal early placental tissues. No
mutation in exons 5-8 was detected in any of these 38 tissue specimens. These results suggest that a mutation
in p53 tumour suppressor either does not exist or is a very rare event in gestational trophoblastic tumours. The
gestational trophoblastic tumours probably involve a tumour-suppressor gene other than p53 gene or may
follow a completely different pathway to their malignant phenotype.
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Gestational trophoblastic diseases are a group of clinically
and histopathologically defined entities with characteristics of
reproductive failure and a high neoplastic potential (Roberts
and Mutter, 1994). Major advances have been achieved
during the past 40 years in the epidemiology, aetiology,
pathology, endocrinology, immunology, diagnosis and
treatment of gestational trophoblastic disease (Lurain,
1990). Early diagnosis and effective treatment of patients
with gestational trophoblastic disease have resulted in almost
100% cure rates in non-metastatic disease and in the majority
of patients with metastases (Lurain, 1990).
However, there is so far no reliable genetic marker for
predicting which subset of moles will behave aggressively.
For the most part, the pathogenesis and aetiology for
hydatidiform mole and choriocarcinoma are still considered
by many as controversial and unclear. Mutation of the p53
gene, which encodes a nuclear phosphoprotein of 393 amino
acids, is the most common genetic alteration in human
cancers (Greenblatt et al., 1994). The p53 protein functions as
tumour suppressor, which negatively regulates cell growth.
Numerous recent reports have shown that missense or
frameshift mutations of the p53 gene can be found in
almost every type of tumour (Greenblatt et al., 1994;
Berchuck et al., 1994) suggesting aberrations of possible
common pathways of growth control in these diverse
malignancies. Although mutations in the p53 gene have
been identified throughout the gene, the vast majority (over
98%) of them locate in exons 5-8 regardless of the tumour
type.
To evaluate the frequency of p53 mutation in the
gestational trophoblastic tumours, we describe here the use
of the polymerase chain reaction (PCR)-based direct DNA
sequencing method to examine the DNA sequences of exons
5-8 of the p53 gene in 28 gestational trophoblastic tumours
and in ten normal early placental tissues. Using this
approach, no mutations were found in either the tumour or
the normal placental tissues.
Materials and methods
Materials
Serial 4-5 gm sections of paraffin-embedded tissues were
prepared from 14 hydatidiform moles, six invasive moles,
eight choriocarcinomas and ten normal early placental
tissues (TableI). All tissues were taken from patients of
the Women's Hospital, Zhejiang Medical University at
Hangzhou and were obtained before any chemotherapy
treatment. The following p53 mutant DNA specimens were
obtained from Dr YS Chang of Chang Gung College of
Medicine and Technology and served as mutant control
DNA in the DNA sequencing experiments: laryngeal
carcinoma no. 28, which contains a GTC to GCG (Val
to Ala) mutation in codon 173 in exon 5; hypopharyngeal
carcinoma no. 35, which contains a GTG to GTTG
frameshift mutation on codon 203 in exon 6; nasophar-
yngeal carcinoma no. 81, which contains a CGG to CAG
(Arg to Gln) mutation in codon 248 in exon 7; and
laryngeal carcinoma no. 22, which contains an 8 bp
deletion in codons 274-276 in exon 8 (Chang et al.,
1992).
Immunohistochemical staining ofp53 protein in trophoblastic
tissues
Sections (4 jgm) of formalin-fixed, paraffin-embedded tissues
were cut. Sections were then deparaffinised, rehydrated and
stained using the avidin-biotin-peroxidase complex meth-
od. Both anti-p53 antibody (clone DO-7) and conjugated
secondary antibody (rabbit anti-mouse horseradish perox-
idase) were obtained from Dako (Copenhagen). p53 staining
results were scored by a modified version of Fromwitz's
method with a combined tally for intensity of stained p53
signal and percentage of cells stained positive for p53
(Fromwitz et al., 1987). Intensity of stained p53 signal was
scored 3, 2, 1 and 0 representing strong, moderate, weak
and negative signals respectively. The percentage of cells
stained positive for p53 was also scored 3, 2, 1 and 0
representing >75%, 50-75%, 25-50% and <25% cells
stained positive for p53 respectively. Therefore, the highest
and lowest possible scores are 6 and 0 respectively. The
Fromwitz scores were determined by C-L Z, who is a
pathologist and had prior knowledge of the histopathologi-
cal findings at the time of scoring.
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Table I Fromwitz scores and histopathological findings of
specimens
Histology
Normal trophoblast
Normal trophoblast
Normal trophoblast
Normal trophoblast
Normal trophoblast
Normal trophoblast
Normal trophoblast
Normal trophoblast
Normal trophoblast
Normal trophoblast
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Hydatidiform mole
Invasive mole
Invasive mole
Invasive mole
Invasive mole
Invasive mole
Invasive mole
Choriocarcinoma
Choriocarcinoma
Choriocarcinoma
Choriocarcinoma
Choriocarcinoma
Choriocarcinoma
Choriocarcinoma
Choriocarcinoma
Fromwitz score
0
0
0
1
0
0
0
0
0
0
1
1
0
1
2
2
2
2
1
2
1
0
0
1
1
3
4
3
3
4
0
5
1
0
3
3
3
et al., 1990). The sequence information for the primers is
listed in Table II. The conditions used for the amplification
reactions have been described earlier (Pao et al., 1994) with
minor modifications. Briefly, approximately 0.5,ug of
purified cellular DNA was amplified with thermostable Taq
DNA polymerase in a Thermal Cycler (Model 480, Perkin-
Elmer Cetus, Norwalk, CT, USA). The 50 ,ul amplification
reaction mixture contained 10 mmol 1-l Tris-HCl, pH 8.3,
50 mmol 1-l potassium chloride; 1.5 mmol 1-l magnesium
chloride; 0.01% gelatin; 10 pmole each of the primers for
the initial amplification; 2.5 nmol each of the four
deoxyribonucleoside triphosphates and 1 unit of Taq DNA
polymerase (Perkin-Elmer Cetus). Amplification reactions
were cycled 45 times beginning with 94°C for 30 s to
denature the target DNA. This process was then followed by
re-naturation for 30s at either 550C or 60°C, depending on
the exons being amplified and primers used for most efficient
amplification. All extension reactions were carried out at
72°C for 60 s. The amplified DNA products were confirmed
by agarose gel electrophoresis. Because of the sensitivity of
the PCR, a number of precautions were taken to minimise
the possibility of contamination during sampling and
subsequent processing (Pao et al., 1991, 1993, 1994).
DNA sequencing analysis
Aliquots of 5 ,l of each of the five sets of the amplification
products were used to generate single-stranded DNA for
subsequent direct sequencing of each exon of the p53 gene.
Two asymmetric amplification reactions, one each with an
excess of one of the primers over the other of opposite
orientation, were performed in order to sequence from both
directions. The single-stranded DNA was purified by
repeated alcohol precipitation and washing. The resus-
pended DNA was then subjected to direct DNA sequencing
using a Sequenase version 2.0 DNA Sequencing kit (United
States Biochemical, Cleveland, OH, USA) according to the
manufacturer's recommendation.
Results
DNA extraction and amplification ofp53 gene DNA sequences
by polymerase chain reaction
Portions of each tissue section that contained cancer cells
were identified under the microscope after haematoxylin and
eosin staining and then removed by dissection for DNA
extraction and subsequent analyses. Total cellular DNA was
extracted from tissues by the standard phenol-chloroform
method and purified by alcohol precipitation before being
used for amplification of p53 gene DNA sequences. A total
of five pairs of oligonucleotide primers based on published
p53 gene DNA sequences were used to amplify exons 5, 6, 7
and 8 (exon 5 was amplified by two pairs of primers) (Soussi
Immunohistochemical staining results indicated that p53
immunoreactivity ranged between 0 and 5 in the tissues
examined (Table I and Figure 1). It appears that there is a
statistically significant difference in the Fromwitz score
among various histological types as determined by analysis
of variance (X2= 11.12, P<0.001). As a group, the invasive
moles appear to have a higher score (mean=3.0) than the
other histological types. The hydatidiform mole group has a
slightly higher profile (mean = 1.143) than the normal
trophoblast group (mean =0.1). The Fromwitz scores of the
choriocarcinoma group are most variable with a mean of 2.0.
Both modified t-test (least square difference or LSD method)
and Duncan's multiple range test confirm that the Fromwitz
Table H Oligonucleotide primers used for p53 gene DNA amplification by polymerase chain reaction and primers
used for direct DNA sequencing
Target DNA Primer sequences (from 5'to 3') Size ofamplified DNA
(in base pairs)
Exon 5a TTCCTCTTCCTGCAGTACTCCCCTGCCCTC 129
GTAGATGGCCATGGCGCGGACG
Exon 5b GTTGATTCCACACCCCCGCCCGGCACCC 127
GCTCACCATCGCTATCTGAGC
Exon 6 GATTGCTCTTAGGTCTGGCCCCTCCTCAGC 130
CAGACCTCAGGCGGCTCATAGG
Exon 7 CTAGGTTGGCTCTGACTGTACCACCATCC 118
TGACCTGGAGTCTTCCAGTGTG
Exon 8 GTAGTGGTAATCTACTGGGACGGAACAGC 141
CTCGCTTAGTGCTCCCTGGGGGC
Exon 5 DNA ofp53 genewasamplified and sequenced in two portions forgreatestefficiency. aTheupstreamportion
ofthe p53 gene. bThe downstream portion ofthe p53 gene.
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Figure 1 Nuclear accumulation of p53 protein in choriocarcino-
ma. Strong p53 expression in the nuclei of choriocarcinoma cells
from case number 33 as shown by immunohistochemistry
(original magnifications x 470 in (a) and x 940 in (b).
scores are significantly associated with histological types,
except between invasive moles and choriocarcinomas.
DNA of exons 5, 6, 7 and 8 of the p53 gene from a total
of 38 tissue specimens (14 hydatidiform moles, six invasive
moles, eight choriocarcinoma and ten normal placental
tissues) were amplified and then sequenced successfully. The
amplified DNA of p53 gene exon 5 (lanes A and B), 6 (lane
C), 7 (lane D) and 8 (lane E) is illustrated in Figure 2. Exon 5
of the p53 gene was amplified and sequenced in two parts for
greatest efficiency. The DNA sequencing results of the p53
gene confirmed that no mutation could be found in exons 5,
6, 7 and 8 of any of the 38 tissues studied (data not shown).
Discussion
We have screened exons 5 -8 of the p53 genes of 14
hydatidiform moles, six invasive moles, eight choriocarcino-
ma and ten normal early placental tissues by PCR
amplification followed by direct DNA sequencing for the
possible presence of genetic aberrations. Our research does
not reveal any DNA sequence alteration in any of these 38
tissues. The regions of p53 genes we have examined include
exons that are known for their functional importance (Ullrich
et al., 1992). The overwhelming majority (over 98%) of p53
gene mutations in tumour tissues and cancer cell lines
reported so far in the literature are clustered within exons
5-8, equivalent to amino acid residues 130 and 290 of p53
protein (Hollstein et al., 1991; Levine et al., 1991). This is
also a region where the DNA sequences are highly conserved
among several different species (Soussi et al., 1990; Pao et al.,
Figure 2 Agarose gel electrophoresis of PCR amplification
products of p53 gene DNA sequences. Plasmid pGEM-3 DNA
digested with a mixture of three restriction endonucleases (Hinfl,
RsaI and SinI) was used as DNA size markers in the two outside
lanes (lanes M), and the sizes of these DNA fragments are (from
top to bottom) 2645, 1605, 1198, 676, 517, 460, 396, 350, 222,
179, 126, 75, 65, 51 and 36bp. Lanes A and B are DNA from
upstream and downstream portions of exon 5 of the p53 gene
respectively. The amplified DNA are 129 and 127 base pairs
respectively. Lanes C, D and E are DNA for exons 6, 7 and 8
respectively and their sizes are 130, 118 and 141 bp respectively.
1994). In order to include any possible mutation that may
occur at the intron-exon splicing junction, we chose to
amplify the individual exon DNAs instead of amplifying the
complete cDNA fragment in one single piece. It is, therefore,
relatively safe to assume that we probably would have
detected p53 mutations if they did exist.
There seems to be a trend between the Fromwitz score and
the histological findings in the tissue specimens. However,
p53 overexpression, as indicated by immunohistochemical
staining, could be the result of actively proliferating cells and
not necessarily due to the presence of a mutant form of p53
protein. This notion was supported by the observations of
p53 overexpression in inflammatory lesions (Bosari et al.,
1993), and in the basal layers of warts and in the basal to
middle third of cervical intraepithelial neoplasia lesions
(Cooper et al., 1993). Therefore, it would not be inconsistent
to state that increased p53 expression correlates with
histological type and that p53 mutations were not observed.
Whether this is really the case would have to be examined
further.
Genetic mutation in tumour-suppressor gene p53 is
thought to contribute to tumour growth by inactivating
proteins that normally act to limit cell proliferation (Ullrich
et al., 1992). A central role for p53 gene in transcription and
phosphorylation events required for passage of a cell from GI
to S-phase and in the decision of a cell to replicate or to go
to apoptosis has become apparent (Levine et al., 1994).
Because of its central role in regulating cell growth and its
potential association with the development of many cancer
types, the structural integrity and expression of the p53 gene
have been studied very extensively. p53 gene mutations are
expected to be present in diverse malignancies and the vast
majority of a large number of tumour types examined so far
do contain mutations in the p53 gene. However, the
mutational status of the p53 gene in gestational trophoblas-
tic tumours has received relatively very little attention.
Cheung et al. (1993) could not find any mutation in exons
5-8 of four hydatidiform moles after performing direct
sequencing on amplified p53 cDNA fragments. On the other
hand, Chen et al. (1994) were able to detect a sole missense
point mutation in codon 295 of the p53 gene of a single
hydatidiform mole patient among 24 patients examined.
When these results and our data are taken together, it can be
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proposed that the p53 gene (or the mutant form of the p53
gene) is either not important or not directly involved in the
oncogenesis of gestational trophoblastic tumours.
The complete lack of mutations in the p53 gene in cancers
or in conditions related to cancer susceptibility are quite rare
and have been reported only in paediatric astrocytomas
(Litofsky et al., 1994), malignant melanoma (Castresana et
al., 1993) and testicular cancer (Fleischhacker et al., 1994).
The reason for and significance of our failing to detect p53
genetic aberrations in gestational trophoblastic tumours are
not completely clear at the present time. It is possible that
some of these tumours contain mutations located outside the
regions ofp53, that we and others (Cheung et al., 1993; Chen
et al., 1994) have examined. However, this prospect is not
very likely because it would suggest involvement of regions of
p53 proteins that are either not known to contain frequent
mutations in cancers or to be considered functionally
important. Another possibility is that there are other
tumour-suppressor genes whose inactivation or loss of
function is important in the carcinogenesis of these
tumours, as has been suggested (Miyamoto et al., 1991).
Furthermore, it is also possible that carcinogenesis of
gestational trophoblastic tumours, or at least certain subsets
of them, may follow a completely different pathway to their
malignant phenotype, such as telomere length and telomerase
activity (Kim et al., 1994; Wynford-Thomas et al., 1995). The
notion that most, if not all, gestational trophoblastic tumours
contain only the wild-type p53 gene and that these tumours
may arise through a transformation process other than
genetic alteration of the p53 gene, is compatible with the
fact that these tumours have an excellent (90-100%)
chemotherapy cure rate. The link between the lack of a p53
mutation and the inherent high sensitivity to chemotherapy
of gestational trophoblastic tumours is underscored by recent
reports that loss of p53 function may reduce the response of
malignant tumours to treatment (El Rouby et al., 1993;
Harris et al., 1993).
In summary, the results of this study indicate that the
gestational trophoblastic tumours either do not contain or
very rarely contain genetic alterations in the functional
important domains of the p53 tumour-suppressor gene. p53
gene may not play an important role in the carcinogenesis of
these tumours. More studies are needed to better define the
aetiology of gestational trophoblastic tumours.
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